Pharma M&A versus alliances and its underlying value drivers
Are M&A or alliances the right therapy for an ailing pharmaceutical industry?- A capital market perspective
(Sprache: Englisch)
This study analyzes 229 M&A and 120 in-licensing deals in the pharmaceutical industry. The author shows from a capital market perspective that M&A experiences significant, negative cumulative average abnormal returns whereas in-licensings are able...
Leider schon ausverkauft
Buch (Gebunden)
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
Produktdetails
Produktinformationen zu „Pharma M&A versus alliances and its underlying value drivers “
This study analyzes 229 M&A and 120 in-licensing deals in the pharmaceutical industry. The author shows from a capital market perspective that M&A experiences significant, negative cumulative average abnormal returns whereas in-licensings are able to create value. Significant determinants of success for both strategies are derived.
Klappentext zu „Pharma M&A versus alliances and its underlying value drivers “
From a capital market perspective, the author analyzes Merger and Acquisitions transactions (M&A) and in-licensings in the pharmaceutical industry between 1998 and 2012. Utilizing the event study methodology, the volume shows that M&A experiences significant, negative cumulative average abnormal returns whereas in-licensings are able to create value. But what are the underlying value drivers which make a deal a success or a failure story? The author derives significant innovative determinants of success for both strategies.
Inhaltsverzeichnis zu „Pharma M&A versus alliances and its underlying value drivers “
Contents: The Pharmaceutical Industry and its Paradigm Shift - The Pharmaceutical Industry and Mergers & Acquisitions - Value Creation in Pharmaceutical M&A and its underlying Value Drivers - The Pharmaceutical Industry and Alliances - Value Creation in Pharmaceutical In-licensings and its underlying Value Drivers - M&A versus In-licensing.
Autoren-Porträt von Heiko Schön
Heiko Schön studied international business administration at Wiesbaden Business School. He was scholar of the German National Merit Foundation (sdw), he owns an Executive MBA from the University of Münster and earned his PhD at the University of Darmstadt. He brings in 10 years of experience in the pharmaceutical and chemical industry.
Bibliographische Angaben
- Autor: Heiko Schön
- 2015, Neuausgabe, 201 Seiten, Maße: 15,3 x 21,6 cm, Gebunden, Englisch
- Verlag: Peter Lang Ltd. International Academic Publishers
- ISBN-10: 3631663811
- ISBN-13: 9783631663813
- Erscheinungsdatum: 28.09.2015
Sprache:
Englisch
Kommentar zu "Pharma M&A versus alliances and its underlying value drivers"
Schreiben Sie einen Kommentar zu "Pharma M&A versus alliances and its underlying value drivers".
Kommentar verfassen